CA2308115A1 - Interaction de peptides d'alpha-conotoxine avec des recepteurs neuraux d'acetylcholine nicotinique - Google Patents

Interaction de peptides d'alpha-conotoxine avec des recepteurs neuraux d'acetylcholine nicotinique Download PDF

Info

Publication number
CA2308115A1
CA2308115A1 CA002308115A CA2308115A CA2308115A1 CA 2308115 A1 CA2308115 A1 CA 2308115A1 CA 002308115 A CA002308115 A CA 002308115A CA 2308115 A CA2308115 A CA 2308115A CA 2308115 A1 CA2308115 A1 CA 2308115A1
Authority
CA
Canada
Prior art keywords
peptide
mii
nachr
alpha
data
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002308115A
Other languages
English (en)
Inventor
Ki-Joon Shon
Baldomero M. Olivera
Jean E. Rivier
Steven C. Koerber
Gregory S. Shen
J. Michael Mcintosh
G. Edward Cartier
Doju Yoshikami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Case Western Reserve University
Cognetix Inc
Salk Institute for Biological Studies
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Case Western Reserve University, Cognetix Inc, Salk Institute for Biological Studies, University of Utah Research Foundation Inc filed Critical Case Western Reserve University
Publication of CA2308115A1 publication Critical patent/CA2308115A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des dérivés du conopeptide MII, peptide de conotoxine d'.alpha.-4/7, dans lequel des résidus aminoacides sont substitués, selon l'invention, tout en conservant l'activité de base de MII. Elle concerne également la découverte de la structure tridimensionnelle de MII et le rapport entre sa structure et sa spécificité pour le sous-type .alpha.3.beta.2 du récepteur neural d'acétylcholine nicotinique (nAChR). Elle concerne également des programmes informatisés servant à l'expression de la structure tridimensionnelle de MII et de ses analogues peptidiques, ses mimétiques peptidiques ou non peptidiques. On peut mettre en corrélation les caractéristiques structurales avec l'activité biologique afin de pouvoir élaborer des analogues et des mimétiques de peptide de conotoxine .alpha.-4/7 qui montrent la même spécificité pour nAChR neural. Ces analogues et ces mimétiques sont utiles en tant qu'agents cardio-vasculaires et servent également à traiter ou à détecter le carcinome pulmonaire à petites cellules (SCLC).
CA002308115A 1997-10-24 1998-10-23 Interaction de peptides d'alpha-conotoxine avec des recepteurs neuraux d'acetylcholine nicotinique Abandoned CA2308115A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6278397P 1997-10-24 1997-10-24
US60/062,783 1997-10-24
US6581497P 1997-11-14 1997-11-14
US60/065,814 1997-11-14
PCT/US1998/022368 WO1999021878A1 (fr) 1997-10-24 1998-10-23 Interaction de peptides d'alpha-conotoxine avec des recepteurs neuraux d'acetylcholine nicotinique

Publications (1)

Publication Number Publication Date
CA2308115A1 true CA2308115A1 (fr) 1999-05-06

Family

ID=26742692

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308115A Abandoned CA2308115A1 (fr) 1997-10-24 1998-10-23 Interaction de peptides d'alpha-conotoxine avec des recepteurs neuraux d'acetylcholine nicotinique

Country Status (5)

Country Link
EP (1) EP1032588A4 (fr)
JP (1) JP2001521042A (fr)
AU (1) AU1114399A (fr)
CA (1) CA2308115A1 (fr)
WO (1) WO1999021878A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853864A (zh) * 2022-06-01 2022-08-05 海南大学 一种nAChR受体α3β2亚型抑制失活型阻断剂、其制备方法及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPP627398A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - II
BR112021007131A2 (pt) * 2018-10-16 2021-08-10 Glo Pharma, Inc. composições de conotoxina de antagonista de peptídeo de receptor nicotínico e métodos relacionados

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447356A (en) * 1981-04-17 1984-05-08 Olivera Baldomero M Conotoxins
EP0496902A1 (fr) * 1991-01-26 1992-08-05 International Business Machines Corporation Système et procédé à base de connaissance pour la recherche de molécules
US5703792A (en) * 1993-05-21 1997-12-30 Arris Pharmaceutical Corporation Three dimensional measurement of molecular diversity
US5514774A (en) * 1993-06-29 1996-05-07 University Of Utah Research Foundation Conotoxin peptides
US5589340A (en) * 1993-06-29 1996-12-31 University Of Utah Research Foundation Process and primers for identifying nucleic acids encoding A-lineage conotoxin peptides
US5633347A (en) * 1993-06-29 1997-05-27 University Of Utah Research Foundation Conotoxin peptides
US5595972A (en) * 1993-06-29 1997-01-21 University Of Utah Research Foundation Conotoxin peptides
JP2001505878A (ja) * 1996-11-18 2001-05-08 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション 心臓血管剤としてのコノトキシンペプチドＩｍＩおよびＭＩＩの使用
US5780433A (en) * 1996-12-06 1998-07-14 University Of Utah Research Foundation Use of α-conotoxin MII to treat disorders resulting from nicotine stimulated dopamine release

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114853864A (zh) * 2022-06-01 2022-08-05 海南大学 一种nAChR受体α3β2亚型抑制失活型阻断剂、其制备方法及应用
CN114853864B (zh) * 2022-06-01 2023-06-20 海南大学 一种nAChR受体α3β2亚型抑制失活型阻断剂、其制备方法及应用

Also Published As

Publication number Publication date
EP1032588A1 (fr) 2000-09-06
EP1032588A4 (fr) 2001-11-28
JP2001521042A (ja) 2001-11-06
AU1114399A (en) 1999-05-17
WO1999021878A1 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
Hwang et al. A ‘three‐pronged’binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome
Katz Binding to protein targets of peptidic leads discovered by phage display: crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence
Benison et al. Structure and dynamics of LC8 complexes with KXTQT-motif peptides: swallow and dynein intermediate chain compete for a common site
Saez et al. A dynamic pharmacophore drives the interaction between Psalmotoxin-1 and the putative drug target acid-sensing ion channel 1a
Tochio et al. Formation of nNOS/PSD-95 PDZ dimer requires a preformed β-finger structure from the nNOS PDZ domain
Huzil et al. A unique mode of microtubule stabilization induced by peloruside A
US20030064921A1 (en) Methods and compounds for modulating melanocortin receptor ligand binding and activity
Le Du et al. 1.9-A resolution structure of fasciculin 1, an anti-acetylcholinesterase toxin from green mamba snake venom.
Strynadka et al. Two trifluoperazine‐binding sites on calmodulin predicted from comparative molecular modeling with troponin‐C
CN116650617A (zh) α-突触核蛋白聚集的基于结构的肽抑制剂
Morita et al. Interaction sites among phospholamban, sarcolipin, and the sarco (endo) plasmic reticulum Ca2+-ATPase
US7196061B2 (en) Compounds that modulate neuronal growth and their uses
US7456153B2 (en) Compounds and methods for modulating functions of classical cadherins
Benjamin et al. Solution structure of the GTPase activating domain of αs
CA2308115A1 (fr) Interaction de peptides d'alpha-conotoxine avec des recepteurs neuraux d'acetylcholine nicotinique
Martín-García et al. Crystallographic structure of the SH3 domain of the human c-Yes tyrosine kinase: loop flexibility and amyloid aggregation
WO1997008300A9 (fr) Proteines cristallines de la famille zap
KR19990063585A (ko) 결정상 ｚａｐ계 단백질
Lubman et al. Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface
Lung et al. Functional preference of the constituent amino acid residues in a phage‐library‐based nonphosphorylated inhibitor of the Grb2‐SH2 domain
Chi et al. Solution conformation of a neuronal nicotinic acetylcholine receptor antagonist α-conotoxin OmIA that discriminates α3 vs. α6 nAChR subtypes
JP2008520734A (ja) Ｐｆ４ファーマコフォア及びそれらの使用
US7869958B2 (en) Structure-based modulators of B1 G-protein coupled receptors
Calvanese et al. Structural insights into the interaction between the Cripto CFC domain and the ALK4 receptor
Marquart Structure and Bioactivity of a Rationally Designed Nicotinic Acetylcholine Receptor Antagonist Targeting the Alpha-3 Beta-2 Subtype

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20021023